{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Medulloblastoma", "query": { "condition": "Refractory Medulloblastoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 109, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Medulloblastoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T20:39:26.374Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04320888", "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent WHO Grade 2 Glioma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory WHO Grade 2 Glioma", "Wilms Tumor" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1, "start_date": "2021-05-03", "completion_date": "2026-06-30", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 172, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04320888" }, { "nct_id": "NCT02748135", "title": "A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)" ], "interventions": [ { "name": "TB-403 20mg/kg", "type": "DRUG" }, { "name": "TB-403 50mg/kg", "type": "DRUG" }, { "name": "TB-403 100mg/kg", "type": "DRUG" }, { "name": "TB-403 175mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncurious NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 18, "start_date": "2016-05", "completion_date": "2020-10-06", "has_results": false, "last_update_posted_date": "2021-01-13", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748135" }, { "nct_id": "NCT02255461", "title": "Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Choroid Plexus Tumor", "Childhood Ependymoblastoma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Anaplastic Oligoastrocytoma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliomatosis Cerebri", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "palbociclib isethionate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 35, "start_date": "2014-12-08", "completion_date": "2019-02-25", "has_results": true, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255461" }, { "nct_id": "NCT02095132", "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Nervous System Embryonal Tumor With Rhabdoid Features", "Central Nervous System Embryonal Tumor, Not Otherwise Specified", "Central Nervous System Ganglioneuroblastoma", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Pineoblastoma", "Primary Central Nervous System Neoplasm", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 76, "start_date": "2014-03-28", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095132" }, { "nct_id": "NCT04023669", "title": "Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor", "Brain Tumor, Recurrent", "Brain Tumor, Refractory", "Brain Tumor, Pediatric", "Medulloblastoma", "Medulloblastoma Recurrent", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, Non-WNT/Non-SHH, Group 3", "Medulloblastoma, Non-WNT/Non-SHH, Group 4", "Brain Cancer", "CNS Cancer", "CNS Tumor", "CNS Neoplasm" ], "interventions": [ { "name": "Prexasertib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "peg-filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "24 Years", "sex": "ALL", "summary": "1 Year to 24 Years" }, "enrollment_count": 21, "start_date": "2019-08-08", "completion_date": "2025-01-13", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023669" }, { "nct_id": "NCT02574728", "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 46, "start_date": "2015-06", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574728" }, { "nct_id": "NCT01076530", "title": "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Extra-adrenal Paraganglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 27, "start_date": "2010-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 7, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076530" }, { "nct_id": "NCT00544284", "title": "Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544284" }, { "nct_id": "NCT00005811", "title": "Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "AIDS-related Small Noncleaved Cell Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "HIV-associated Hodgkin Lymphoma", "Leptomeningeal Metastases", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 77, "start_date": "2000-04", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-02-21", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005811" }, { "nct_id": "NCT00994071", "title": "A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Medulloblastoma", "Pontine Glioma", "Ependymoma", "Astrocytoma", "PNET" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 9, "start_date": "2009-09-22", "completion_date": "2013-03-19", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-05-21T20:39:26.374Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994071" } ] }